ADULT MEDICATION GUIDELINE	
Oxytocin	
Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology
This document should be read in conjunction with the Disclaimer.	

Quick Links

Dose	Administration	Monitoring	Pregnancy and Breastfeeding

Restrictions

Formulary: Unrestricted

Medication Class

Oxytocic (synthetic pituitary hormone)

Presentation

Ampoule: 10unit/mL

Combination Product:

Ampoule: Oxytocin 5unit Ergometrine 500microg per 1mL (Refer to KEMH Adult Medication Guideline: Syntometrine)

Storage

Protect from light.

Store at 2 - 8°C (Refrigerate. Do not freeze)*

**May be stored for up to 30 days, at or below 25°C. If stock is removed from the refrigerator, ensure the date of removal is clearly written on the blue and white stickers (7b) provided by pharmacy.*

Dose and Administration

Prophylaxis and Treatment of Postpartum Haemorrhage:

Refer to: KEMH O&G Restricted Area Clinical Practice Guideline: Postpartum Complications *(Intranet access only)*

Refer to: KEMH Community Midwifery Program Clinical Practice Guideline: Primary Postpartum Haemorrhage (PPH) at Home (CMP) *(Intranet access only)*

Induction of Labour:

Refer to: KEMH O&G Restricted Area Clinical Practice Guideline: Induction of Labour *(Intranet access only)*

Pharmacological management of uterine tone at caesarean birth:

Refer to: KEMH O&G Clinical Practice Guideline: Caesarean birth

Active management of the third stage of labour:

Refer to: KEMH O&G Clinical Practice Guideline: Labour: Third stage

Retained Placenta:

Refer to: KEMH O&G Clinical Practice Guideline: Labour: Third stage: Retained Placenta

Monitoring

When using an infusion, monitor fluid balance to prevent water intoxication.

Pregnancy

1st Trimester: Consider alternative

2nd Trimester: Consider alternative

3rd Trimester: Monitoring required

Breastfeeding

Safe to use

Comments

Do not use ampoules that have been out of the fridge for more than 30 days or if the date of removal from the fridge is unknown.

Related Policies, Procedures & Guidelines

WNHS O&G Clinical Practice Guidelines (in addition to those listed above):

- Blood Products and Transfusion: Refusal
- Bladder Management
- Birth After Previous Caesarean Section
- Fetal Heart Rate Monitoring
- Multiple Pregnancy
- Rupture of Membranes- Spontaneous (Pre-viability, Preterm and Term)
- Cardiac Disease
- Labour: First Stage: Management of Delay
- Labour: Second Stage: Management of Delay
- Abnormalities of lie / presentation
- Body Mass Index (BMI) >40: Management of a Woman with

WNHS Medicines Management Guidelines:

Structured Administration & Supply Arrangement (SASA): CMP Oxytocin

References

Australian Medicines Handbook. Oxytocin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Mar 24]. Available from: https://amhonline.amh.net.au/

The Royal Women's Hospital. Oxytocin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2021 Mar 24]. Available from: https://thewomenspbmg.org.au/

Nguyen TH, Lambert P, Minhas RS, McEvoy C, Deadman K, Wright P, Prankerd RJ, Mogatle S, McIntosh MP. Temperature stability of oxytocin ampoules labelled for storage at 2°C-8°C and below 25°C: an observational assessment under controlled accelerated and temperature cycling conditions. BMJ Open. 2019 Jul 26;9(7):e029083. doi: 10.1136/bmjopen-2019-029083. PMID: 31350247; PMCID: PMC6661635.

American Society of Health-System Pharmacists. Oxytocin. In: AHFS Drug Information [Internet]. Bethesda, MD: American Society of Health-System Pharmacists; 2021 [cited 2021 Mar 24]. Available from: https://online-statref-

com.kelibresources.health.wa.gov.au/document/cQfe8yqMRNqgSGqm4Qo8Qj

Keywords	Oxytocin, induction, labour, oxytocic, labour, IOL, induction of labour, PPH, postpartum haemorrhage				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0				
Date First Issued:	May 2016	Last Reviewed:	2017, amended 2019, 2021, June 2024	Review Date:	June 2029
Endorsed by:	Medicines and Therapeutics Committee			Date:	06/02/2024
NSQHS Standards Applicable:	☒ Std 1: Clinical Governance ☐ Std 2: Partnering with Consumers ☐ Std 3: Preventing and Controlling Healthcare Associated Infection ☒ Std 4: Medication Safety			☐ Std 5: Comprehensive Care ☐ Std 6: Communicating for Safety ☐ Std 7: Blood Management ☐ Std 8: Recognising and Responding to Acute Deterioration	
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2024

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.